XTRA:CNWK

Stock Analysis Report

Executive Summary

co.don AG engages in cell cultivation for the regenerative treatment of articular cartilage and spinal disc defects worldwide.

Snowflake

Fundamentals

Mediocre balance sheet with limited growth.

Share Price & News

How has co.don's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.1%

CNWK

1.3%

DE Biotechs

3.9%

DE Market


1 Year Return

-42.6%

CNWK

1.7%

DE Biotechs

3.4%

DE Market

Return vs Industry: CNWK underperformed the German Biotechs industry which returned 1.7% over the past year.

Return vs Market: CNWK underperformed the German Market which returned 3.4% over the past year.


Shareholder returns

CNWKIndustryMarket
7 Day3.1%1.3%3.9%
30 Day3.1%-5.0%2.1%
90 Day-33.8%-4.5%3.7%
1 Year-42.1%-42.6%1.8%1.7%6.7%3.4%
3 Year-8.0%-9.1%69.2%67.5%18.9%8.6%
5 Year7.4%-4.1%14.0%11.5%41.8%22.5%

Price Volatility Vs. Market

How volatile is co.don's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is co.don undervalued compared to its fair value and its price relative to the market?

4.57x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate CNWK's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate CNWK's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CNWK is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: CNWK is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate CNWK's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CNWK is overvalued based on its PB Ratio (4.6x) compared to the DE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is co.don forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

53.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CNWK is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CNWK is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CNWK is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CNWK's revenue (37.7% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: CNWK's revenue (37.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: CNWK's Return on Equity is forecast to be low in 3 years time (10.8%).


Next Steps

Past Performance

How has co.don performed over the past 5 years?

-33.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CNWK is unprofitable, and losses have increased over the past 5 years at a rate of -33.6% per year.

Accelerating Growth: Unable to compare CNWK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CNWK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Return on Equity

High ROE: CNWK has a negative Return on Equity (-90.26%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: CNWK is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: CNWK is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is co.don's financial position?


Financial Position Analysis

Short Term Liabilities: CNWK's short term assets (€9.1M) exceeds its short term liabilities (€3.3M)

Long Term Liabilities: CNWK's short term assets (9.1M) do not cover its long term liabilities (9.9M)


Debt to Equity History and Analysis

Debt Level: CNWK is debt free.

Reducing Debt: CNWK has not had any debt for past 5 years.


Balance Sheet

Inventory Level: CNWK has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if CNWK's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if CNWK has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CNWK has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is co.don's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage0.8%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate CNWK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CNWK's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if CNWK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CNWK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CNWK's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of co.don's salary, the management and board of directors tenure and is there insider trading?

5.1yrs

Average board tenure


CEO

Ralf Jakobs 0

0.8yrs

Tenure

€286,000

Compensation

Mr. Ralf M. Jakobs has been Chief Financial Officer and Member of Executive Board at co.don AG since February 1, 2016 and May 1, 2016 respectively. He serves as Chief Executive Officer of co.don AG since 2 ...


CEO Compensation Analysis

Compensation vs. Market: Ralf has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the German market.

Compensation vs Earnings: Ralf's compensation has been consistent with company performance over the past year.


Board Age and Tenure

5.1yrs

Average Tenure

Experienced Board: CNWK's board of directors are considered experienced (5.1 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Matthias Meissner

    Director of Corporate Communications

    • Tenure: 0yrs
  • Ralf Jakobs

    CFO, CEO & Member of Management Board

    • Tenure: 0.8yrs
    • Compensation: €286.00k
  • Tilmann Bur (54yo)

    COO & Additional Member of Executive Board

    • Tenure: 0.3yrs

Board Members

  • Thomas Krause

    Member of the Supervisory Board

    • Tenure: 7.1yrs
  • Hans-Joerg Bullinger (75yo)

    Member of Supervisory Board

    • Tenure: 0.8yrs
  • Thommy Stählin

    Member of the Supervisory Board

    • Tenure: 13.9yrs
  • Hans Bauerfeind

    Chairman of Supervisory Board

    • Tenure: 1.8yrs
  • Beatrix Bauerfeind-Johnson

    Member of Supervisory Board

    • Tenure: 3.2yrs
  • Barbara Sickmüller

    Member of the Supervisory Board

    • Tenure: 9.3yrs

Company Information

co.don AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: co.don AG
  • Ticker: CNWK
  • Exchange: XTRA
  • Founded: 1993
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €57.409m
  • Shares outstanding: 21.75m
  • Website: https://www.codon.de

Number of Employees


Location

  • co.don AG
  • Warthestrasse 21
  • Teltow
  • Brandenburg
  • 14513
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CNWKDB (Deutsche Boerse AG)YesCommon SharesDEEURFeb 2001
CNWKXTRA (XETRA Trading Platform)YesCommon SharesDEEURFeb 2001
0Q37LSE (London Stock Exchange)YesCommon SharesGBEURFeb 2001
CNWKdBATS-CHIXE (BATS 'Chi-X Europe')YesCommon SharesGBEURFeb 2001

Biography

co.don AG engages in cell cultivation for the regenerative treatment of articular cartilage and spinal disc defects worldwide. The company develops, produces, and markets autologous cell therapies for the  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 20:56
End of Day Share Price2019/10/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.